Tyra Biosciences Q2 2025 cash $296.3M; dosed first patient in SURF302 NMIBC trial

Tyra Biosciences, Inc.

2025-Q2 EPS reported -$0.95 vs consensus -$0.54 ▼ miss (-76.2%)

Cash, cash equivalents and marketable securities of $296.3M as of June 30, 2025; runway through at least 2027.
Q2 net loss of $28.1M, vs $18.7M in Q2 2024; R&D expenses $24.3M (up from $18.0M).
Dosed first patient in SURF302 Phase 2 study of dabogratinib for FGFR3-altered intermediate-risk NMIBC.
BEACH301 Phase 2 achondroplasia study now enrolling safety sentinel cohort; dose first child expected 3Q 2025.
Initial three-month complete response data from SURF302 expected in first half 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.